An immunotherapy skin patch increased the proportion of children aged 4 to 7 years who could tolerate a dose of peanut protein. The study took place in III. phase called VITESSE. It is immunotherapy for peanut allergy delivered through an investigational skin patch. It tamed allergic reactions in children. The study was conducted in Philadelphia and was published on MedPage Today. The main finding is the higher tolerance of peanut protein after treatment.